Dr. Karmali on the Impact of CAR T-Cell Therapy in DLBCL

Reem Karmali, MD
Published: Thursday, Dec 14, 2017



Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with diffuse large B-cell lymphoma (DLBCL).

Patients who are refractory to chemotherapy now have CAR T-cell therapy as an option, according to Karmali. The SCHOLAR-1 study investigated the outcomes of patients with refractory DLBCL, which showed a median overall survival of 6 months. The addition of CAR T-cell therapy has benefitted this patient population, says Karmali.
 


Reem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with diffuse large B-cell lymphoma (DLBCL).

Patients who are refractory to chemotherapy now have CAR T-cell therapy as an option, according to Karmali. The SCHOLAR-1 study investigated the outcomes of patients with refractory DLBCL, which showed a median overall survival of 6 months. The addition of CAR T-cell therapy has benefitted this patient population, says Karmali.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x